AR036827A1 - Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas - Google Patents

Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas

Info

Publication number
AR036827A1
AR036827A1 ARP020103870A ARP020103870A AR036827A1 AR 036827 A1 AR036827 A1 AR 036827A1 AR P020103870 A ARP020103870 A AR P020103870A AR P020103870 A ARP020103870 A AR P020103870A AR 036827 A1 AR036827 A1 AR 036827A1
Authority
AR
Argentina
Prior art keywords
keratinocytes
keratinocits
active substance
biologically active
wound treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP020103870A
Other languages
English (en)
Inventor
Petra Eberhardt
Katharina Reif
Wolfgang Noe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR036827A1 publication Critical patent/AR036827A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Abstract

Reivindicación 1: Queratinocitos, caracterizados porque no están inmortalizados y que se duplican mediante procedimiento de cultivo celular in vitro al menos 150 veces. Reivindicación 9: Producto formado por un soporte, que está recubierto con queratinocitos según una de las reivindicaciones 1-8, a) estando cubierto parcialmente el soporte con queratinocitos; ó b) estando cubierto totalmente el soporte con queratinocitos. Reivindicación 14: Procedimiento para la crioconservación de queratinocitos según las reivindicaciones 1-8 ó de un producto según las reivindicaciones 9-13, en el que los queratinocitos ó el producto se crioconservan a una temperatura de -20°C hasta -196°C, preferiblemente de -60°C hasta -80°C. Reivindicación 17: Uso de queratinocitos según las reivindicaciones 1-8 y 15 o de un producto según las reivindicaciones 10-13 y 15 para el tratamiento de heridas.
ARP020103870A 2001-10-17 2002-10-16 Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas Suspension/Interruption AR036827A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (de) 2001-10-17 2001-10-17 Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden

Publications (1)

Publication Number Publication Date
AR036827A1 true AR036827A1 (es) 2004-10-06

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103870A Suspension/Interruption AR036827A1 (es) 2001-10-17 2002-10-16 Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas

Country Status (30)

Country Link
US (3) US7247478B2 (es)
EP (1) EP1440148B1 (es)
JP (1) JP4476625B2 (es)
KR (1) KR101019916B1 (es)
CN (1) CN100432220C (es)
AR (1) AR036827A1 (es)
AT (1) ATE474039T1 (es)
AU (1) AU2002349352B2 (es)
BR (1) BR0213282A (es)
CA (1) CA2461141C (es)
CO (1) CO5580844A2 (es)
DE (2) DE10151296A1 (es)
DK (1) DK1440148T3 (es)
EA (1) EA009073B1 (es)
EC (1) ECSP045065A (es)
ES (1) ES2345767T3 (es)
HR (1) HRP20040347B1 (es)
HU (1) HU228887B1 (es)
IL (2) IL161442A0 (es)
MX (1) MXPA04003487A (es)
MY (1) MY137828A (es)
NO (1) NO334974B1 (es)
NZ (1) NZ532899A (es)
PE (1) PE20030627A1 (es)
PL (1) PL367338A1 (es)
RS (1) RS30104A (es)
UA (1) UA81398C2 (es)
UY (1) UY27486A1 (es)
WO (1) WO2003033686A2 (es)
ZA (1) ZA200402306B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PT3100611T (pt) * 2003-08-01 2018-12-14 Stratatech Corp Equivalentes de pele humana que expressam polipéptidos exógenos
WO2006010161A2 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2702973C (en) * 2007-10-19 2017-01-24 John D. Jarrell Method of making a composition from metal oxide and polymer precursors
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EP2711423B1 (en) * 2010-06-09 2014-11-05 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854824A1 (en) * 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN105219697A (zh) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 一种人原代角质细胞分离制备的方法
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
CN109153968A (zh) * 2016-04-12 2019-01-04 联合细胞Ev股份公司 从生物流体样品中分离细胞外囊泡（ev）
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN109055303A (zh) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 一种皮肤组织的构建方法
RU2731065C1 (ru) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Состав криоконсерванта для длительного хранения первичных кератиноцитов

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) * 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (it) 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (it) 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US6585969B1 (en) * 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
ATE193057T1 (de) * 1991-11-20 2000-06-15 Innogenetics Nv Lysate von keratinozyten zur verwendung als heilmittel für wunden.
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5891617A (en) * 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5693332C1 (en) * 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (de) 1999-04-19 2000-10-26 Christian Toloczyki Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten

Also Published As

Publication number Publication date
KR20040045856A (ko) 2004-06-02
US20030091542A1 (en) 2003-05-15
ZA200402306B (en) 2006-05-31
DE10151296A1 (de) 2003-04-30
CO5580844A2 (es) 2005-11-30
PL367338A1 (en) 2005-02-21
IL161442A (en) 2012-02-29
HUP0600341A3 (en) 2011-03-28
MXPA04003487A (es) 2004-07-30
ECSP045065A (es) 2004-05-28
JP2005505392A (ja) 2005-02-24
NO20041570L (no) 2004-04-16
CN100432220C (zh) 2008-11-12
EA200400482A1 (ru) 2004-12-30
HU228887B1 (hu) 2013-06-28
JP4476625B2 (ja) 2010-06-09
PE20030627A1 (es) 2003-07-16
UY27486A1 (es) 2003-05-30
EP1440148A2 (de) 2004-07-28
ES2345767T3 (es) 2010-10-01
DK1440148T3 (da) 2010-09-27
IL161442A0 (en) 2004-09-27
HRP20040347A2 (en) 2005-04-30
US7306943B2 (en) 2007-12-11
DE50214540D1 (de) 2010-08-26
CA2461141A1 (en) 2003-04-24
WO2003033686A2 (de) 2003-04-24
EP1440148B1 (de) 2010-07-14
US20080131967A1 (en) 2008-06-05
EA009073B1 (ru) 2007-10-26
CN1571835A (zh) 2005-01-26
NZ532899A (en) 2006-04-28
NO334974B1 (no) 2014-08-11
MY137828A (en) 2009-03-31
HRP20040347B1 (en) 2012-07-31
HUP0600341A2 (en) 2006-08-28
AU2002349352B2 (en) 2007-11-01
CA2461141C (en) 2011-12-06
KR101019916B1 (ko) 2011-03-08
BR0213282A (pt) 2004-10-26
US20070065419A1 (en) 2007-03-22
ATE474039T1 (de) 2010-07-15
UA81398C2 (en) 2008-01-10
US7754481B2 (en) 2010-07-13
RS30104A (en) 2006-10-27
US7247478B2 (en) 2007-07-24
WO2003033686A3 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
AR036827A1 (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas
Muthukumar et al. Fish scale collagen sponge incorporated with Macrotyloma uniflorum plant extract as a possible wound/burn dressing material
ATE277648T1 (de) Kollagenmembran mit makromolekularer anordnung
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
WO2000073421A3 (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
DK1131410T3 (da) Gensplejsede vævskonstruktioner og fremgangsmåde til fremstilling og anvendelse deraf
AR015257A1 (es) UNA COMPOSICION ACIDIFICADA Y EL USO DE DICHA COMPOSICION PARA LA MANUFACTURA DE UN MEDICAMENTO PARA EL TRATAMIENTO ToPICO DE CONDICIONES DE LAS UNAS Y DE LA PIEL
ATE309326T1 (de) Verfahren zur konservierung eukariotischen zellen und dadurch hergestellte zusammensetzungen
WO2002002593A3 (en) Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
AR023546A1 (es) Disulfuros ciclicos de pirrolidincarbonilamina
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
ATE329632T1 (de) Verfahren zur entwicklung von epithelialen stammzellen
ES2048142T3 (es) Procedimiento de obtencion de polidesoxirribonucleotidos sustancialmente puros y no informacionales que tienen actividades biologicas, y producto respectivo.
WO2007075796A3 (en) Stage specific follicle maturation systems
WO2004078944A3 (en) Thrombin, soluble jaggedi, and trap and growth of stem cells
ES2059119T3 (es) Hidroxicarboxilatos sulfitados.
WO2007005659A3 (en) Methods and compositions for culturing keratinocytes
DE60132466D1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
O'Leary et al. The use of an in vitro wound healing model, the tri-layered skin equivalent, to study the effects of cytokines on the repopulation of the wound defect by fibroblasts and keratinocytes

Legal Events

Date Code Title Description
FB Suspension of granting procedure